Edition:
United Kingdom

Clementia Pharmaceuticals Inc (CMTA.OQ)

CMTA.OQ on NASDAQ Stock Exchange Global Select Market

17.63USD
20 Apr 2018
Change (% chg)

$-1.81 (-9.31%)
Prev Close
$19.44
Open
$19.45
Day's High
$19.45
Day's Low
$17.00
Volume
11,120
Avg. Vol
15,450
52-wk High
$20.12
52-wk Low
$11.77

Chart for

About

Clementia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and... (more)

Overall

Beta: --
Market Cap(Mil.): $593.43
Shares Outstanding(Mil.): 33.66
Dividend: --
Yield (%): --

Financials

  CMTA.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -4.30 -- --
ROI: -129.19 -0.74 13.19
ROE: -- -2.80 15.00

BRIEF-Clementia Pharmaceuticals Inc Q4 2017 Loss Per Share $0.37

* Q4 EARNINGS PER SHARE VIEW $-0.35 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

28 Feb 2018

BRIEF-Clementia Initiates Pivotal Phase 3 MOVE Trial For Palovarotene

* CLEMENTIA INITIATES PIVOTAL PHASE 3 MOVE TRIAL FOR PALOVAROTENE IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA

12 Dec 2017

BRIEF-Clementia Pharmaceuticals qtrly loss per share ‍$1.83​

* Clementia Pharmaceuticals Inc - qtrly loss per share ‍$1.83​

13 Nov 2017

Earnings vs. Estimates